1Ruggiero M, Melli M, Parma B, et al. Isolation of endogenous anti- coagulant N-sulfated glycosaminoglycans in human plasma from healthy subjects [J]. Pathophysiol Haemost Thromb, 2002, 32: 44-49.
2Sucker C, Mansmann G, Steiner S, et al. Fatal bleeding due to a hep- arin-like anticoagulant in a 37-year-old woman suffering from sys- temic mastocytosis [J]. Clin Appl Thromb Hemost, 2008, 14: 360-364.
3Bussel JB, Steinherz PG, Miller DR, et al. A heparin-like anticoagu- lant in an 8-month-old boy with acute monoblastie leukemia [J]. Am J Pathol, 1984, 16: 83-90.
4Home MK, Chao ES, Wilson OJ, et al. A heparin-like anticoagulant as part ofglobal abnormalities of plasma glycosaminoglycans in a patient with transitional cell carcinoma [J]. J Lab Clin Med, 1991, 118: 250-260.
5Palmer P.N, Rick ME, Rick PD, et al. Circulating heparan sulfate an- ticoagulant in a patient with a fatal bleeding disorder [J]. N Engl J Med, 1984, 310: 1696-1699.
6Wintrobe MM, Lee GR, Boggs DR, et al. Clinical Hematology [M]. 8~ Ed. Philadelphia: Lea& Febiger, 1981: 1206-1246.
7Khoory MS, Nesheim ME, Bowie EJW, et al. Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder [J]. J Clin Invest, 1980, 65: 666-674.
8Tefferi A, Nichols WL, Bowie EJ. Circulating heparin-like anticoag- ulants: report of five consecutive cases and a review [J]. Am J Med, 1990, 88: 184-188.
9Fahl KN, Pooh SA, Badani KK, et al. Paraneoplastic production of hepariu-like anticoagulant in a patient with metastatic transitional cell carcinoma [J]. Can Urol Assoc J, 2009, 3(5): 61-63.
10Jarosova A, Filip V, Monhart V, et al. Circulating hepariu-iike a~ati- coagulant-2 cases of successful therapy [J]. Vnitr Lek, 1992, 38: 513-517.
